Cancer patient recieving chemotherapy treatment

How to Evaluate a Chemotherapy Centre: The Hidden Factors Patients Often Miss

By Dr. Salil Patkar

When it comes to picking a chemotherapy centre, there are more factors to consider than simply if chemotherapy is offered or if the hospital has an oncology department. 

The safe use of systemic anti-cancer drugs requires precise prescribing, regimen-dependent monitoring, trained preparation of the drug, supervision of the infusion and management of drug related toxicity and prompt access to medical assessment in the event of drug-related complications occurring between courses.

These systems can be just as important as appearance and size for patients who receive repeat treatment.

1. Look Beyond the Chemotherapy Chair

Administering chemotherapy is just one component of the broader clinical treatment. The oncology team may want to assess treatment appropriateness at the planned dose and schedule before an intravenous infusion is started, or before an oral chemotherapy medication is prescribed to be continued.

This assessment will differ depending on the type of cancer, chemotherapy treatment plan, and the purpose of treatment, as well as the known side effects of chemotherapy. This can include examination, full blood count, renal and liver function tests, review of symptoms and performance status.

The reason is pharmacological as well as practical.

A lot of the cytotoxic agents are toxic to rapidly growing malignant cells and have a potential to be toxic to normal proliferating tissue. Bone marrow precursor cells are noteworthy. They may cause a decrease in the number of circulating neutrophils, platelets or red blood cells, which can result in neutropenia, thrombocytopenia or anaemia.

Other medications have other toxic side effects that limit the dosage that can be given. Clinicians might be concerned about peripheral neuropathy, renal impairment, hepatic dysfunction or cardiac toxicity, depending on the agent.

A good chemotherapy centre should have protocols to determine if the patient is clinically appropriate for the next cycle of treatment, however, not a fixed regimen.

YouTube video

2. Ask Who Actually Makes Treatment Decisions

A chemotherapy unit should not function simply as an infusion facility.

Medical oncologists determine systemic treatment based on variables such as tumour type, histopathology, stage, relevant molecular findings, previous treatment, organ function, physiological reserve and the objective of therapy.

That objective deserves particular attention.

Chemotherapy given with curative intent is clinically different from adjuvant chemotherapy intended to reduce recurrence risk after definitive local treatment. Neoadjuvant treatment may be used to reduce tumour burden before surgery, while palliative systemic therapy in advanced cancer may aim to control disease, prolong survival or reduce cancer-related symptoms.

These differences influence how oncologists interpret treatment response, toxicity, dose intensity and treatment duration.

Patients can therefore ask a more useful question than simply, “Which chemotherapy will I receive?”

Ask: What is the treatment intent, and what clinical factors determine whether this regimen remains appropriate for me?

A centre should be able to explain that distinction clearly.

3. Examine How Chemotherapy Is Prescribed and Prepared

Chemotherapy prescribing requires multiple layers of accuracy.

The correct drug alone is not sufficient. A prescription may also depend on dose, route, administration sequence, infusion duration, cycle interval and supportive medicines. Some doses are calculated using body surface area, while certain agents use other dosing approaches. Renal or hepatic impairment can also affect the suitability or dosing of particular drugs.

Drug preparation is another largely invisible part of chemotherapy care.

Antineoplastic medicines require controlled handling because preparation errors can have serious consequences and healthcare workers need protection from occupational exposure. Patients evaluating a centre can ask whether chemotherapy is prepared by appropriately trained personnel using established protocols for cytotoxic medicines.

This is one of the hidden differences between receiving an infusion and receiving chemotherapy within a properly governed oncology system.

4. Find Out What Is Checked Before Each Cycle

A common misconception is that once a chemotherapy plan has been prescribed, every cycle proceeds exactly as scheduled.

Clinical practice is more conditional.

Consider myelosuppression. After certain chemotherapy regimens, blood counts may fall and subsequently recover before the next planned cycle. A complete blood count can provide information about haemoglobin, platelets and white blood cells. The absolute neutrophil count, or ANC, is particularly relevant when evaluating infection risk and marrow recovery with many regimens.

But a single laboratory value does not determine the entire treatment decision.

The oncologist may also consider fever or infection, mucositis, diarrhoea, neuropathy, renal or hepatic function, previous toxicity, general clinical condition and regimen-specific treatment criteria.

If recovery is inadequate or toxicity has become clinically significant, treatment may sometimes require a delay or dose modification.

Neither automatically means that chemotherapy has “failed”. They are clinical management decisions intended to balance anticancer treatment with patient safety.

A useful chemotherapy centre should have a defined pre-treatment assessment process rather than relying only on whether the patient has arrived on the scheduled date.

5. Check How the Centre Handles Complications Between Cycles

Much of chemotherapy safety happens after the patient leaves the infusion unit.

One important example is febrile neutropenia.

Neutropenia means that circulating neutrophils, white blood cells central to defence against bacterial and fungal infection, have fallen. Febrile neutropenia refers to fever occurring in the setting of significant neutropenia and can require urgent medical assessment because infection may progress rapidly when neutrophil-mediated immune defence is impaired.

The risk is not identical with every chemotherapy regimen or patient. It is influenced by the drugs used, dose intensity, age, comorbidities, marrow reserve, previous treatment and other clinical factors.

Patients should know exactly how the centre wants them to report fever or other concerning symptoms and where they should seek assessment outside normal clinic hours.

The same principle applies to persistent vomiting or diarrhoea, significant dehydration, breathing difficulty, altered consciousness, uncontrolled bleeding and other potentially serious complications.

An emergency plan should exist before it is needed.

6. Evaluate the Nursing and Infusion Safety System

Oncology nursing is a specialised component of chemotherapy care.

During intravenous treatment, trained staff need to verify the prescribed therapy, monitor administration and recognise infusion-related problems. Certain agents can cause hypersensitivity or infusion reactions. Some chemotherapy drugs are also vesicants or irritants, meaning leakage outside the vein can damage surrounding tissue.

That makes vascular access management clinically important.

Depending on treatment duration, drug characteristics and venous access, chemotherapy may be delivered through a peripheral intravenous cannula or a central venous access device. The appropriate approach is patient and regimen dependent.

Patients do not need to become experts in infusion medicine. They should, however, determine whether the unit has oncology-trained staff, defined medication-verification procedures and protocols for managing acute treatment reactions.

7. Ask How Toxicity Is Tracked Across Multiple Cycles

Chemotherapy toxicity is not limited to what happens during an infusion.

Some adverse effects emerge after treatment, recur with successive cycles or become more important as cumulative exposure increases. Peripheral neuropathy associated with some agents, for example, may progressively affect sensation or function. Other treatments can require closer monitoring of renal, hepatic or cardiac function.

This is why continuity matters.

A centre should have a reliable way of documenting toxicities from previous cycles and incorporating them into subsequent treatment decisions.

A patient who reports increasing numbness, reduced oral intake or prolonged diarrhoea should not have that information treated as an isolated complaint. It may influence toxicity grading, supportive care, dose modification or the timing of subsequent treatment.

Good chemotherapy care therefore involves longitudinal clinical assessment, not merely successful completion of individual infusions.

8. Consider Access to Multidisciplinary and Supportive Care

Chemotherapy rarely exists in isolation from the rest of cancer management.

Depending on the malignancy, treatment may need coordination between medical oncology, surgical oncology, radiation oncology, pathology, radiology and other specialties. Nutrition, pain management, psycho-oncology, rehabilitation and palliative care may also become relevant.

Supportive care should not be confused with stopping cancer treatment.

Its purpose includes preventing or managing treatment-related complications, controlling symptoms and maintaining function while cancer-directed treatment continues when appropriate.

For patients travelling considerable distances for treatment in India, coordination becomes especially important. A centre should explain which problems can be managed locally, which require review by the treating oncology team and how urgent complications will be handled if the patient is away from the primary hospital.

9. Do Not Judge Quality by Cost or Infrastructure Alone

A modern infusion suite can improve comfort, but it does not by itself demonstrate clinical quality.

Likewise, the most expensive facility is not automatically the most appropriate centre for every patient. A more useful evaluation considers whether the centre can reliably provide the systems surrounding systemic anticancer therapy:

  • medical oncologist-led treatment planning

  • appropriate pre-cycle clinical and laboratory assessment

  • safe cytotoxic drug preparation and administration

  • trained oncology nursing

  • documentation of cumulative and previous toxicities

  • access to supportive care

  • clear pathways for urgent complications

  • multidisciplinary coordination when required

  • continuity across repeated treatment cycles

Practical considerations still matter. Chemotherapy may require multiple visits over several months, so travel time, accommodation, affordability and access to investigations can affect whether a treatment plan is realistically sustainable.

Questions Worth Asking Before Choosing a Centre

Before committing to treatment, patients and caregivers can ask:

  • Who is responsible for prescribing and reviewing the chemotherapy regimen?

  • What assessments are performed before each treatment cycle?

  • Where and by whom are chemotherapy medicines prepared?

  • Are chemotherapy infusions supervised by oncology-trained nurses?

  • How are previous side effects documented before the next cycle?

  • Whom should we contact if fever or another concerning symptom develops at home?

  • Is urgent oncology assessment available outside routine clinic hours?

  • Can the centre coordinate with surgery, radiation oncology and other specialists if required?

  • How will treatment response and toxicity be assessed over time?

  • If treatment needs to be delayed or modified, how will the reason be explained?

Indian Cancer Treatment Centre is not simply capable of administering an anticancer drug. What we excel in is the clinical system around that drug: why a particular regimen was selected, whether the patient is fit to receive each cycle, how treatment is prepared and monitored, how toxicities influence subsequent decisions, and what happens when complications occur between scheduled visits.

Those are the less visible factors patients often miss, and ICTC makes sure they are central to safe, medically responsible chemotherapy care Mumbai.

About the Author

Dr. Salil Patkar

Dr. Salil Patkar

MD Internal Medicine, DM Medical Oncology, Certified in Immuno-Oncology and Precision Oncology (Harvard Medical School)

Dr. Salil Vijay Patkar is a senior Medical Oncologist with over 12 years of extensive clinical experience, specialising in the comprehensive management of solid tumors and hematological malignancies. He is the Founder and Director of the Indian Cancer Treatment Centre (ICTC), an institution established with the vision of delivering evidence-based, modern, and patient-centric cancer care through a network of centres across Mumbai. Dr. Patkar completed his MD in Internal Medicine from KLES University’s Jawaharlal Nehru Medical College and Dr. Prabhakar Kore Hospital, followed by a DM in Medical Oncology from the Gujarat Cancer & Research Institute (GCRI), Ahmedabad, one of India’s most respected and high-volume comprehensive cancer centres. His training at GCRI provided in-depth exposure to complex oncological cases, multidisciplinary tumour boards, protocol-driven cancer management, and advanced chemotherapy and immunotherapy practices. To further strengthen his expertise in advanced cancer therapeutics, Dr. Patkar completed a Certificate Program in Cancer Genomics, Precision Oncology, and Immuno-Oncology from Harvard Medical School. This training equipped him with a strong foundation in molecular diagnostics, targeted therapies, and personalised treatment planning. He has also pursued a postgraduate academic program affiliated with Johns Hopkins School of Medicine, reflecting his commitment to continuous learning and global medical education standards. Clinically, Dr. Patkar has deep expertise in immunotherapy, molecular-targeted therapy, chemotherapy, and precision oncology, enabling him to design individualised treatment plans based on tumour biology, genetic markers, and patient-specific factors. He is also skilled in performing bone marrow aspiration and biopsy and is actively involved in the management of both hematological cancers and solid tumours. Prior to founding ICTC, Dr. Patkar held several leadership and consultant roles at prominent healthcare institutions. He served as the Head of the Medical Oncology Department at MPCT Hospitals and has worked as a Consultant Medical Oncologist at Apollo Hospitals, gaining extensive experience across institutional oncology programs and private cancer care delivery. In addition to his clinical work, Dr. Patkar has contributed to oncology research and academic initiatives. He was a Co-investigator in the PROMISE clinical registry at GCRI, focusing on diffuse large B-cell lymphoma and chronic lymphocytic leukemia. He has authored and co-authored clinical case reports and studies, including work on rare cancer presentations and colorectal cancer clinical profiles. Dr. Patkar’s professional excellence has been recognised through multiple academic and professional awards, including Student of the Year (Delcure Lifesciences, 2013) and First Prize in the Lung Cancer Quiz at GCRI (2017). He is widely respected for his structured clinical approach, strong patient communication skills, and unwavering commitment to ethical oncology practice. As the Founder and Director of ICTC, Dr. Patkar continues to lead a multidisciplinary oncology team focused on delivering high-quality cancer care using globally aligned treatment protocols. His work reflects a balance of advanced science, clinical precision, and compassionate care, ensuring that patients receive timely, transparent, and effective oncology treatment close to home.